Pyxis Oncology, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022; filed May 13, 2022. Pyxis is a preclinical-stage oncology biotechnology company with no approved products or revenue. Its portfolio includes ADC and immuno-oncology candidates, all still in preclinical development.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 / prior date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $20.1 million | $32.8 million |
| General and administrative expense | $11.3 million | $3.0 million |
| Total operating expenses | $31.4 million | $35.7 million |
| Net loss | $31.4 million | $36.8 million |
| Net loss per share, basic and diluted | $0.97 | $27.26 |
| Cash used in operating activities | $27.7 million | $18.7 million |
| Cash and cash equivalents at period end | $247.1 million | $274.7 million at Dec. 31, 2021 |
| Total liabilities | $19.2 million | $18.7 million at Dec. 31, 2021 |
There is no meaningful operating margin to assess given the absence of revenue. The filing reports no debt. Total assets were $252.7 million and stockholders’ equity was $233.5 million at March 31, 2022. Management expected existing cash to fund operations and capital needs into the third quarter of 2024, subject to assumptions and potential changes in its operating plan; the liquidity note separately says cash was expected to cover at least 12 months from issuance of the financial statements.
Material changes and notable items
- Net loss improved by $5.4 million year over year, mainly because R&D expense fell $12.7 million. The filing attributes the R&D decline chiefly to $19.4 million less in licensing fees, partly offset by increased cell-line development and personnel costs. Q1 2021 included substantial Pfizer and LegoChem licensing costs.
- G&A expense rose $8.4 million, reflecting higher headcount, legal and other professional fees, and directors’ and officers’ insurance costs.
- Operating cash use increased by $8.9 million year over year. Q1 2022 included a $9.6 million payment to LegoChem; a $10.0 million Biosion license fee was expensed and accrued in Q1, then paid in April 2022.
- In March 2022, Pyxis licensed PYX-106 from Biosion, with an upfront fee of $10 million and potential development, regulatory, and commercial milestones of up to $217.5 million for normal approval or $222.5 million for accelerated approval, plus royalties.
- The reported per-share loss is not directly comparable year over year: weighted-average shares were 32.3 million in Q1 2022 versus 1.35 million in Q1 2021, following the 2021 financing and IPO-related share conversion.
Outlook, risks, and contingencies
- Management expected IND submissions for PYX-201 and PYX-106 in the second half of 2022, and for PYX-203 and PYX-102 in the second half of 2023. PYX-202 required additional GLP and non-GLP toxicity studies; management expected to provide an update in mid-2022.
- Management expects operating losses and negative cash flows to continue, with expenses increasing as programs advance. Additional capital may be needed; financing could dilute shareholders or require less favorable terms.
- Key risks include preclinical and regulatory failure or delay, reliance on third-party manufacturers and research providers, competition, intellectual-property and licensing obligations, and possible COVID-19-related disruption. The company had not experienced material COVID-19 business disruption to date.
- The company disclosed a Boston office and laboratory lease extending to December 2032, with $33.8 million of undiscounted base-rent payments; it expected to take possession in Q2 2022. The filing reports no material legal proceedings.
- Management concluded disclosure controls and procedures were effective at the reasonable-assurance level; no material change in internal control over financial reporting was identified.
Important facts for investors to verify
- Whether the stated cash runway into Q3 2024 remains valid as spending and development plans evolve.
- Progress and timing of the planned IND submissions, particularly the additional toxicity work and status of PYX-202.
- Cash burn, the impact of the Biosion license and future milestone or royalty obligations under licensing agreements.
- The timing and financial impact of commencing occupancy under the long-term Boston lease.
- The balance-sheet restricted cash is reported as $1.472 million, while the cash-flow reconciliation lists $1.580 million at March 31, 2022; confirm the correct amount.